Enanta Pharmaceuticals | ENTA - Sales Revenues


Enanta Pharmaceuticals reported $16.96M in Sales Revenues for its fiscal quarter ending in December of 2024.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Anika Therapeutics USD 26.17M 12.58M Mar/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Incyte USD 1.51B 140M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
J&J USD 24.6B 610M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Merck USD 16.4B 880M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Novavax USD 84.51M 330.97M Sep/2024
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025